CoChat

Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008–2016

Deluche, Elise, Antoine, Alison, Bachelot, Thomas, Lardy-Cleaud, Audrey, Dieras, Veronique, Brain, Etienne, Debled, Marc, Jacot, William, Mouret-Reynier, Marie Ange, Goncalves, Anthony, Dalenc, Florence, Patsouris, Anne, Ferrero, Jean Marc, Levy, Christelle, Lorgis, Veronique, Vanlemmens, Laurence, Lefeuvre-Plesse, Claudia, Mathoulin-Pelissier, Simone, Petit, Thierry, Uwer, Lionel, Jouannaud, Christelle, Leheurteur, Marianne, Lacroix-Triki, Magali, Courtinard, Coralie, Perol, David, Robain, Mathieu, Delaloge, Suzette · 2020 · European Journal of Cancer
Cited by 186

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

AIM Real-world data inform the outcome comparisons and help the development of new therapeutic strategies. To this end, we aimed to describe the full characteristics and outcomes in the Epidemiological Strategy and Medical Economics (ESME) cohort, a large national contemporary observational database of patients with metastatic breast cancer (MBC). METHODS Women aged ≥18 years with newly diagnosed MBC and who initiated MBC treatment between January 2008 and December 2016 in one of the 18 French Comprehensive Cancer Centers (N = 22,109) were included. We assessed the full patients' characteristics, first-line treatments, overall survival (OS) and first-line progression-free survival, as well as updated prognostic factors in the whole cohort and among the 3 major subtypes: hormone receptor positive and HER2-negative (HR+/HER2-, n = 13,656), HER2-positive (HER2+, n = 4017) and triple-negative (n = 2963) tumours. RESULTS The median OS of the whole cohort was 39.5 months (95% confidence interval [CI], 38.7-40.3). Five-year OS was 33.8%. OS differed significantly between the 3 subtypes (p < 0.0001) with a median OS of 43.3 (95% CI, 42.5-44.5) in HR+/HER2-; 50.1 (95% CI, 47.6-53.1) in HER2+; and 14.8 months (95% CI, 14.1-15.5) in triple-negative subgroups, respectively. Beyond performance status, the following variables had a constant significant negative prognostic impact on OS in the whole cohort and among subtypes: older age at diagnosis of metastases (except for the triple-negative subtype), metastasis-free interval between 6 and 24 months, presence of visceral metastases and number of metastatic sites ≥ 3. CONCLUSIONS The ESME program represents a unique large-scale real-life cohort on MBC. This study highlights important situations of high medical need within MBC patients. DATABASE REGISTRATION: clinicaltrials.gov Identifier NCT032753.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ejca.2020.01.016

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 23

  1. Cardoso, 2018, 4th ESO–ESMO International Consensus guidelines for advanced breast cancer (ABC 4)†, Ann Oncol, 29, 1634, 10.1093/annonc/mdy192 · DOI · Paper page
  2. Ferlay, 2018, Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018, Eur J Canc, 103, 356, 10.1016/j.ejca.2018.07.005 · DOI · Paper page
  3. Gobbini, 2018, Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort, Eur J Canc, 96, 17, 10.1016/j.ejca.2018.03.015 · DOI · Paper page
  4. von Minckwitz, 2017, Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer, N Engl J Med, 377, 122, 10.1056/NEJMoa1703643 · DOI · Paper page
  5. Skovlund, 2018, The use of real-world data in cancer drug development, Eur J Canc, 101, 69, 10.1016/j.ejca.2018.06.036 · DOI
  6. Singh, 2018, Real world big data for clinical research and drug development, Drug Discov Today, 23, 652, 10.1016/j.drudis.2017.12.002 · DOI
  7. Schurman, 2019, The framework for FDA's real-world evidence program, Appl Clin Trials, 28, 15
  8. Khozin, 2017, Real-world data for clinical evidence generation in oncology, J Natl Cancer Inst, 109, 10.1093/jnci/djx187 · DOI · Paper page
  9. Jacquet, 1990, Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients, Eur J Cancer Oxf Engl, 95, 93, 10.1016/j.ejca.2018.03.013 · DOI
  10. Pérol, 2019, The ongoing French metastatic breast cancer (MBC) cohort: the example-based methodology of the Epidemiological Strategy and Medical Economics (ESME), BMJ Open, 9, 10.1136/bmjopen-2018-023568 · doi:10.1136/bmjopen-2018-023568
  11. Wolff, 2007, American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer, J Clin Oncol Off J Am Soc Clin Oncol, 25, 118, 10.1200/JCO.2006.09.2775 · DOI · Paper page
  12. Wolff, 2014, Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update, Arch Pathol Lab Med, 138, 241, 10.5858/arpa.2013-0953-SA · DOI · Paper page
  13. Wolff, 2018, Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/College of American pathologists clinical practice guideline focused update, J Clin Oncol, 36, 2105, 10.1200/JCO.2018.77.8738 · DOI · Paper page
  14. Caswell-Jin, 2018, Change in survival in metastatic breast cancer with treatment advances: meta-analysis and systematic review, JNCI Cancer Spectr, 2, 10.1093/jncics/pky062 · DOI · Paper page
  15. Krop, 2017, Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial, Lancet Oncol, 18, 743, 10.1016/S1470-2045(17)30313-3 · DOI · Paper page
  16. Diéras, 2017, Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial, Lancet Oncol, 18, 732, 10.1016/S1470-2045(17)30312-1 · DOI · Paper page
  17. Yardley, 2014, Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer, Breast Canc Res Treat, 145, 725, 10.1007/s10549-014-2916-8 · DOI
  18. Loibl, 2017, HER2-positive breast cancer, Lancet, 389, 2415, 10.1016/S0140-6736(16)32417-5 · DOI · Paper page
  19. Largillier, 2008, Prognostic factors in 1038 women with metastatic breast cancer, Ann Oncol, 19, 10.1093/annonc/mdn424 · DOI · Paper page
  20. Lobbezoo, 2015, Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?, Br J Canc, 112, 1445, 10.1038/bjc.2015.127 · DOI · Paper page
  21. Ruiterkamp, 2009, Surgical resection of the primary tumour is associated with improved survival in patients with distant metastatic breast cancer at diagnosis, Eur J Surg Oncol, 35, 1146, 10.1016/j.ejso.2009.03.012 · DOI · Paper page
  22. Hartkopf, 2018, Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors – data from the German PRAEGNANT breast cancer registry, Breast, 37, 42, 10.1016/j.breast.2017.10.002 · DOI
  23. Saux, 2019, Assessment of the efficacy of successive endocrine therapies in hormone receptor–positive and HER2-negative metastatic breast cancer: a real-life multicentre national study, Eur J Canc, 118, 131, 10.1016/j.ejca.2019.06.014 · DOI

Cited by

  • 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

    Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M. S., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G. S., Biganzoli, L., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.010 · Cited by 1,369

    “Survival is strongly related to breast cancer subtype, with the major advances seen in human epidermal growth factor receptor 2 (HER2)-positive ABC.(5-9) ABC is a treatable disease with several available therapies and many others in development.”
    Background

Metadata

Authors
Deluche, E., Antoine, A., Bachelot, T., Lardy-Cleaud, A., Dieras, V., Brain, E., Debled, M., Jacot, W., Mouret-Reynier, M. A., Goncalves, A., Dalenc, F., Patsouris, A., Ferrero, J. M., Levy, C., Lorgis, V., Vanlemmens, L., Lefeuvre-Plesse, C., Mathoulin-Pelissier, S., Petit, T., Uwer, L., Jouannaud, C., Leheurteur, M., Lacroix-Triki, M., Courtinard, C., Perol, D., Robain, M., & Delaloge, S.
Venue
European Journal of Cancer
Publisher
Elsevier BV
Published
2020-04
Volume
129
Pages
60-70
ISSN
0959-8049 (ISSN-L)
OpenAlex
W3009223368
Cited by
186
References
2
FWCI
8.05
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Funders
  • Roche
  • AstraZeneca
  • Pfizer
  • Les Laboratories Pierre Fabre

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.